Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Cirrhosis | 20 | 2019 | 908 | 2.760 |
Why?
|
| Liver Transplantation | 19 | 2019 | 1132 | 2.390 |
Why?
|
| Glomerular Filtration Rate | 10 | 2023 | 567 | 1.670 |
Why?
|
| Hepatorenal Syndrome | 4 | 2018 | 31 | 1.560 |
Why?
|
| Waiting Lists | 8 | 2020 | 242 | 1.380 |
Why?
|
| Liver Failure, Acute | 4 | 2015 | 96 | 1.370 |
Why?
|
| Kidney | 6 | 2019 | 1283 | 1.250 |
Why?
|
| Kidney Diseases | 4 | 2015 | 472 | 1.250 |
Why?
|
| Fasting | 2 | 2020 | 303 | 1.160 |
Why?
|
| Cystatin C | 4 | 2018 | 71 | 1.120 |
Why?
|
| Creatinine | 9 | 2023 | 397 | 1.040 |
Why?
|
| End Stage Liver Disease | 5 | 2020 | 191 | 0.950 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 135 | 0.940 |
Why?
|
| Renal Insufficiency | 2 | 2018 | 251 | 0.790 |
Why?
|
| Liver | 6 | 2017 | 1802 | 0.760 |
Why?
|
| Metabolic Syndrome | 2 | 2020 | 366 | 0.690 |
Why?
|
| Factor VIIa | 6 | 2005 | 20 | 0.680 |
Why?
|
| Metabolomics | 3 | 2023 | 500 | 0.660 |
Why?
|
| Circadian Clocks | 1 | 2020 | 86 | 0.570 |
Why?
|
| Proteome | 1 | 2020 | 288 | 0.560 |
Why?
|
| Health Status Disparities | 2 | 2012 | 276 | 0.560 |
Why?
|
| Severity of Illness Index | 10 | 2019 | 3053 | 0.540 |
Why?
|
| Ascites | 2 | 2015 | 98 | 0.540 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 483 | 0.540 |
Why?
|
| Middle Aged | 32 | 2020 | 28448 | 0.510 |
Why?
|
| Liver Failure | 4 | 2017 | 99 | 0.490 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 130 | 0.490 |
Why?
|
| Liver Cirrhosis, Alcoholic | 3 | 2009 | 40 | 0.470 |
Why?
|
| Patient Discharge | 1 | 2019 | 510 | 0.460 |
Why?
|
| Biomarkers | 12 | 2023 | 3397 | 0.460 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 34 | 0.450 |
Why?
|
| Sildenafil Citrate | 1 | 2015 | 55 | 0.450 |
Why?
|
| Living Donors | 2 | 2014 | 112 | 0.450 |
Why?
|
| Tissue and Organ Procurement | 5 | 2019 | 253 | 0.440 |
Why?
|
| Acute Kidney Injury | 2 | 2019 | 684 | 0.430 |
Why?
|
| Renal Plasma Flow | 1 | 2014 | 4 | 0.430 |
Why?
|
| Renal Circulation | 1 | 2014 | 41 | 0.430 |
Why?
|
| Hepatitis C, Chronic | 5 | 2012 | 366 | 0.410 |
Why?
|
| Blood Coagulation Disorders | 3 | 2003 | 105 | 0.410 |
Why?
|
| Vascular Resistance | 1 | 2014 | 182 | 0.400 |
Why?
|
| Humans | 53 | 2023 | 130574 | 0.390 |
Why?
|
| Hemodynamics | 2 | 2014 | 809 | 0.390 |
Why?
|
| Arginine | 1 | 2015 | 335 | 0.380 |
Why?
|
| Adult | 25 | 2019 | 31202 | 0.370 |
Why?
|
| Fatty Liver | 3 | 2014 | 222 | 0.360 |
Why?
|
| Resource Allocation | 1 | 2012 | 52 | 0.360 |
Why?
|
| Male | 29 | 2020 | 64557 | 0.340 |
Why?
|
| Female | 32 | 2020 | 70509 | 0.340 |
Why?
|
| Kidney Transplantation | 3 | 2015 | 564 | 0.330 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 845 | 0.330 |
Why?
|
| Aged | 18 | 2019 | 20925 | 0.320 |
Why?
|
| Valproic Acid | 1 | 2010 | 155 | 0.310 |
Why?
|
| Polyethylene Glycols | 2 | 2008 | 235 | 0.310 |
Why?
|
| Interferon-alpha | 2 | 2008 | 240 | 0.300 |
Why?
|
| Liver Diseases | 2 | 2010 | 382 | 0.280 |
Why?
|
| Graft Rejection | 4 | 2019 | 558 | 0.280 |
Why?
|
| Interferons | 1 | 2008 | 136 | 0.270 |
Why?
|
| Hepatitis B | 2 | 2006 | 172 | 0.270 |
Why?
|
| Biological Specimen Banks | 1 | 2008 | 63 | 0.260 |
Why?
|
| Liver Neoplasms | 3 | 2009 | 1394 | 0.260 |
Why?
|
| HIV | 1 | 2008 | 177 | 0.250 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 218 | 0.250 |
Why?
|
| HELLP Syndrome | 1 | 2006 | 13 | 0.250 |
Why?
|
| Catheter Ablation | 1 | 2009 | 318 | 0.240 |
Why?
|
| Bile Ducts | 1 | 2006 | 53 | 0.240 |
Why?
|
| Risk Factors | 12 | 2019 | 10993 | 0.240 |
Why?
|
| Virus Activation | 1 | 2006 | 86 | 0.240 |
Why?
|
| Vasoconstrictor Agents | 2 | 2018 | 137 | 0.230 |
Why?
|
| Recombinant Proteins | 7 | 2008 | 1312 | 0.230 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2005 | 6 | 0.230 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 10 | 0.230 |
Why?
|
| Hepatitis B virus | 1 | 2006 | 137 | 0.230 |
Why?
|
| Graft Survival | 4 | 2019 | 462 | 0.230 |
Why?
|
| Piperazines | 1 | 2007 | 270 | 0.220 |
Why?
|
| Hypertension, Portal | 1 | 2005 | 79 | 0.220 |
Why?
|
| Vena Cava, Inferior | 1 | 2005 | 95 | 0.210 |
Why?
|
| Tissue Donors | 2 | 2018 | 501 | 0.210 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 107 | 0.210 |
Why?
|
| Hepatocytes | 1 | 2005 | 234 | 0.210 |
Why?
|
| Time Factors | 6 | 2019 | 6223 | 0.210 |
Why?
|
| Survival Rate | 4 | 2019 | 2136 | 0.210 |
Why?
|
| Prochlorperazine | 1 | 2003 | 2 | 0.200 |
Why?
|
| Heparin | 1 | 2005 | 204 | 0.200 |
Why?
|
| Antiemetics | 1 | 2003 | 21 | 0.200 |
Why?
|
| United States | 8 | 2017 | 11820 | 0.200 |
Why?
|
| Splenic Artery | 1 | 2003 | 24 | 0.200 |
Why?
|
| Jehovah's Witnesses | 1 | 2003 | 17 | 0.200 |
Why?
|
| Pyrimidines | 1 | 2007 | 450 | 0.200 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2003 | 43 | 0.200 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 192 | 0.200 |
Why?
|
| Pilot Projects | 2 | 2020 | 1456 | 0.200 |
Why?
|
| Pericardiocentesis | 1 | 2003 | 17 | 0.200 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 169 | 0.200 |
Why?
|
| Treatment Outcome | 6 | 2018 | 12891 | 0.190 |
Why?
|
| Postoperative Complications | 3 | 2019 | 3114 | 0.190 |
Why?
|
| Intracranial Hemorrhages | 1 | 2003 | 78 | 0.190 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 207 | 0.190 |
Why?
|
| Hepatitis C | 1 | 2006 | 388 | 0.180 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 627 | 0.180 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 658 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 1791 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 616 | 0.180 |
Why?
|
| Retrospective Studies | 11 | 2019 | 17653 | 0.180 |
Why?
|
| Cholestasis | 1 | 2003 | 164 | 0.170 |
Why?
|
| Embolization, Therapeutic | 1 | 2003 | 226 | 0.170 |
Why?
|
| Sex Factors | 2 | 2018 | 1336 | 0.170 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 539 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 1003 | 0.160 |
Why?
|
| Necrosis | 2 | 2014 | 194 | 0.160 |
Why?
|
| Databases, Factual | 3 | 2018 | 1221 | 0.160 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1410 | 0.160 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2020 | 329 | 0.150 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 150 | 0.150 |
Why?
|
| Comorbidity | 3 | 2013 | 1595 | 0.150 |
Why?
|
| Immune System | 1 | 2020 | 98 | 0.150 |
Why?
|
| Adiposity | 1 | 2020 | 208 | 0.150 |
Why?
|
| Bilirubin | 2 | 2012 | 127 | 0.150 |
Why?
|
| Cytoskeleton | 1 | 2020 | 167 | 0.150 |
Why?
|
| Aftercare | 1 | 2019 | 152 | 0.140 |
Why?
|
| Lypressin | 1 | 2018 | 18 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 289 | 0.140 |
Why?
|
| Donor Selection | 1 | 2018 | 58 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2018 | 3712 | 0.130 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 5221 | 0.130 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 744 | 0.130 |
Why?
|
| Narcotics | 1 | 2017 | 59 | 0.130 |
Why?
|
| Drug Therapy | 1 | 2017 | 83 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2019 | 229 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 373 | 0.130 |
Why?
|
| Drug Overdose | 1 | 2017 | 70 | 0.120 |
Why?
|
| DNA Repair | 1 | 2020 | 580 | 0.120 |
Why?
|
| Models, Biological | 2 | 2013 | 1390 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2020 | 804 | 0.120 |
Why?
|
| Proteomics | 1 | 2020 | 606 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 296 | 0.110 |
Why?
|
| Glucose | 1 | 2020 | 848 | 0.110 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 238 | 0.110 |
Why?
|
| Disease Progression | 3 | 2013 | 2201 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1387 | 0.110 |
Why?
|
| Adolescent | 7 | 2018 | 20774 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2017 | 484 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 1076 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 226 | 0.110 |
Why?
|
| Factor VII | 2 | 2005 | 17 | 0.110 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2014 | 4 | 0.110 |
Why?
|
| beta 2-Microglobulin | 1 | 2014 | 35 | 0.110 |
Why?
|
| Lipocalin-2 | 1 | 2014 | 28 | 0.110 |
Why?
|
| Prognosis | 4 | 2019 | 4927 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 45 | 0.110 |
Why?
|
| Lipocalins | 1 | 2014 | 31 | 0.110 |
Why?
|
| Cognition | 1 | 2020 | 816 | 0.110 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2014 | 40 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 567 | 0.110 |
Why?
|
| Iothalamic Acid | 1 | 2013 | 4 | 0.100 |
Why?
|
| Receptors, Virus | 1 | 2014 | 96 | 0.100 |
Why?
|
| Diuretics | 1 | 2014 | 158 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2014 | 5085 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1489 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2006 | 2097 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2015 | 285 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 411 | 0.090 |
Why?
|
| Length of Stay | 1 | 2017 | 1396 | 0.090 |
Why?
|
| Organ Size | 1 | 2012 | 424 | 0.090 |
Why?
|
| Likelihood Functions | 1 | 2011 | 117 | 0.090 |
Why?
|
| Young Adult | 5 | 2019 | 9991 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 591 | 0.080 |
Why?
|
| Sodium | 1 | 2012 | 279 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2010 | 122 | 0.080 |
Why?
|
| Antiviral Agents | 2 | 2006 | 809 | 0.080 |
Why?
|
| Infant | 3 | 2010 | 13306 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2010 | 14987 | 0.070 |
Why?
|
| Ribavirin | 2 | 2006 | 86 | 0.070 |
Why?
|
| Hospitalization | 1 | 2017 | 1932 | 0.070 |
Why?
|
| Prevalence | 1 | 2015 | 2683 | 0.070 |
Why?
|
| Thrombomodulin | 2 | 2005 | 18 | 0.070 |
Why?
|
| Thromboplastin | 2 | 2005 | 16 | 0.070 |
Why?
|
| Anticonvulsants | 1 | 2010 | 384 | 0.070 |
Why?
|
| Erythrocyte Indices | 1 | 2007 | 12 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2008 | 6773 | 0.060 |
Why?
|
| Prothrombin Time | 1 | 2007 | 36 | 0.060 |
Why?
|
| Biopsy | 2 | 2012 | 1238 | 0.060 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 47 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2007 | 64 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2010 | 1509 | 0.060 |
Why?
|
| Aspartate Aminotransferases | 1 | 2007 | 80 | 0.060 |
Why?
|
| Alkaline Phosphatase | 1 | 2007 | 95 | 0.060 |
Why?
|
| Logistic Models | 1 | 2011 | 1814 | 0.060 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2006 | 9 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2007 | 156 | 0.060 |
Why?
|
| Benzamides | 1 | 2007 | 125 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2007 | 102 | 0.060 |
Why?
|
| Recurrence | 2 | 2009 | 1479 | 0.060 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2006 | 75 | 0.060 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2005 | 13 | 0.060 |
Why?
|
| Atrophy | 1 | 2006 | 243 | 0.060 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 24 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2006 | 167 | 0.060 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 43 | 0.060 |
Why?
|
| Hepatectomy | 1 | 2006 | 125 | 0.060 |
Why?
|
| Endoscopy, Digestive System | 1 | 2006 | 153 | 0.060 |
Why?
|
| Phlebography | 1 | 2005 | 43 | 0.060 |
Why?
|
| Factor VIII | 1 | 2005 | 50 | 0.060 |
Why?
|
| Iliac Vein | 1 | 2005 | 28 | 0.060 |
Why?
|
| von Willebrand Diseases | 1 | 2005 | 55 | 0.060 |
Why?
|
| Blood Platelets | 2 | 2004 | 316 | 0.060 |
Why?
|
| Diseases in Twins | 1 | 2005 | 88 | 0.060 |
Why?
|
| Femoral Vein | 1 | 2005 | 48 | 0.050 |
Why?
|
| Twins, Monozygotic | 1 | 2005 | 124 | 0.050 |
Why?
|
| Dissection | 1 | 2005 | 58 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 63 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 1165 | 0.050 |
Why?
|
| Child | 3 | 2010 | 26145 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 47 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 394 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2004 | 42 | 0.050 |
Why?
|
| Collateral Circulation | 1 | 2004 | 40 | 0.050 |
Why?
|
| Pre-Eclampsia | 1 | 2006 | 221 | 0.050 |
Why?
|
| Jaundice, Obstructive | 1 | 2003 | 5 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 941 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 546 | 0.050 |
Why?
|
| Catheterization | 1 | 2005 | 231 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2003 | 45 | 0.050 |
Why?
|
| Triglycerides | 1 | 2006 | 604 | 0.050 |
Why?
|
| Platelet Count | 1 | 2003 | 139 | 0.050 |
Why?
|
| Pregnancy | 2 | 2006 | 7492 | 0.050 |
Why?
|
| Integrins | 1 | 2003 | 90 | 0.050 |
Why?
|
| Epilepsy | 1 | 2010 | 879 | 0.050 |
Why?
|
| Mice | 1 | 2020 | 18224 | 0.050 |
Why?
|
| Cause of Death | 2 | 2019 | 509 | 0.050 |
Why?
|
| Registries | 1 | 2009 | 1594 | 0.050 |
Why?
|
| Colonic Polyps | 1 | 2003 | 85 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 228 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2003 | 219 | 0.040 |
Why?
|
| Probability | 2 | 2014 | 306 | 0.040 |
Why?
|
| Stents | 1 | 2005 | 783 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2003 | 1232 | 0.040 |
Why?
|
| Incidence | 1 | 2006 | 3344 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 33899 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 253 | 0.030 |
Why?
|
| Allografts | 1 | 2018 | 218 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2003 | 744 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2009 | 2099 | 0.030 |
Why?
|
| Camptothecin | 1 | 2014 | 78 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 518 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 132 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2004 | 66 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 3844 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2306 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 783 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2012 | 97 | 0.020 |
Why?
|
| Serum | 1 | 2012 | 43 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2932 | 0.020 |
Why?
|
| Brain | 1 | 2003 | 3189 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1892 | 0.020 |
Why?
|
| Sepsis | 1 | 2009 | 496 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2004 | 43 | 0.010 |
Why?
|
| P-Selectin | 1 | 2004 | 69 | 0.010 |
Why?
|
| Causality | 1 | 2004 | 91 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2004 | 98 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 122 | 0.010 |
Why?
|
| Thrombophilia | 1 | 2004 | 41 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2004 | 116 | 0.010 |
Why?
|
| Hemostasis | 1 | 2004 | 76 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 205 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2003 | 18 | 0.010 |
Why?
|
| E-Selectin | 1 | 2003 | 38 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 122 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 3816 | 0.010 |
Why?
|
| Viral Load | 1 | 2004 | 402 | 0.010 |
Why?
|
| Hepacivirus | 1 | 2004 | 273 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 680 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2003 | 261 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2003 | 246 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2004 | 492 | 0.010 |
Why?
|
| Myocardium | 1 | 2004 | 864 | 0.010 |
Why?
|
| Thrombosis | 1 | 2004 | 495 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 2121 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1601 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 3413 | 0.010 |
Why?
|